| Literature DB >> 28499455 |
Shamila D Alipoor1,2,3, Esmaeil Mortaz4,5,6, Payam Tabarsi1, Parissa Farnia7, Mehdi Mirsaeidi8, Johan Garssen9,10, Masoud Movassaghi11, Ian M Adcock12,13.
Abstract
BACKGROUND: Tuberculosis (TB) remains a significant global health concern and its diagnosis is challenging due to the limitations in the specificity and sensitivity of the current diagnostic tests. Exosomes are bioactive 30-100 nm vesicles produced by most cell types and are found in almost all human body fluids. Exosomal microRNAs (miRNAs) can transfer biological information between cells and tissues and may act as potential biomarkers in many diseases. In this pilot study, we assessed the miRNA profile of exosomes released from human monocyte-derived macrophages upon infection with Mycobacterium bovis Bacillus Calmette-Guerin (BCG).Entities:
Keywords: Biomarker; Exosome; Macrophage; Mycobacterium; miRNA
Mesh:
Substances:
Year: 2017 PMID: 28499455 PMCID: PMC5427544 DOI: 10.1186/s12967-017-1205-9
Source DB: PubMed Journal: J Transl Med ISSN: 1479-5876 Impact factor: 5.531
Fig. 1Exosome characterization by scanning (SEM) and transmission electron microscopy (TEM) and nanoanalyzer. Exosomes were isolated by total exosome isolation reagents and passed twice through a 0.22 mm filter before being analyzed for morphology by SEM (a) and TEM (b). The size distribution of the isolated exosomes was further analyzed by nanoanalyzer (c) and showed the size distribution of the exosomes as 70 ± 3.4 nm. The results are representative of three independent experiments
Fig. 2Exosomal RNA qualification. Total RNA was extracted from the exosomes and the quality of the exosomal RNA was assessed by running the samples on an Agilent Bioanalyzer. The RNA population observed in the exosomes were predominantly from small RNAs. The result is representative of three independent experiments
Exosomal miRNA content in infected and uninfected macrophage-derived exosomes
| Infected exosomal miRNAs | Uninfected exosomal miRNA | |
|---|---|---|
| Common miRNAs according to expression level | mir-486, mir-21, mir-146a, mir-92a, mir-146b, let-7i, mir-423, mir-378a, let-7f, let-7g, let-7a, mir-155, mir-320a, mir-191, let-7b, mir-24-, mir-26a, mir-423, mir-140, mir-30d, mir-148a, mir-101, mir-221, mir-103a, let-7e, mir-28, mir-1307, mir-151a, mir-148b, mir-26b, mir-27a, mir-532, let-7d, mir-361, mir-99b, mir-342, mir-941, mir-511 | mir-21, mir-146b, mir-146a, let-7f, let-7i, let-7a, mir-378a, let-7g, let-7b, mir-26a, mir-191, mir-423, mir-30d, mir-155, mir-320a, mir-511, mir-423, mir-1307, mir-101, mir-24, mir-92a, mir-148a, mir-99b, mir-532, let-7d, mir-486, let-7e, mir-103a, mir-221, mir-26b, mir-140, mir-148b, mir-28, mir-151a, mir-941, mir-342, mir-27a, mir-361 |
Differentially expressed exosomal miRNAs (p < 0.05) obtained from three independent experiments. 44 and 47 miRNAs were identified in the M.tb-infected and -uninfected macrophage-derived exosomes with a copy number >20
Differentially expressed microRNAs in the exosomes released specifically from M.tb-infected cells
| miRNA name | Log Fc | Log CPM | p value | FDR |
|---|---|---|---|---|
| hsa-miR-96 | 5.89073 | 2.930204 | 0.000245 | 0.000186 |
| hsa-miR-1224 | 5.217967 | 3.015217 | 0.000519 | 0.000361 |
| hsa-miR-1293 | 3.171918 | 14.19242 | 0.00203 | 0.001093 |
| hsa-miR-4467 | 3.174797 | 12.62878 | 0.00204 | 0.001093 |
| hsa-miR-6848 | 4.143784 | 3.760948 | 0.00578 | 0.002233 |
| hsa-miR-6849 | 3.118348 | 7.30397 | 0.00826 | 0.003 |
| hsa-miR-4488 | 3.184877 | 5.073045 | 0.000404 | 0.010436 |
| hsa-miR-425 | 3.481839 | 4.249725 | 0.000572 | 0.012611 |
| hsa-miR-4732 | 2.578799 | 8.273334 | 0.000616 | 0.013178 |
| hsa-miR-484 | 2.389806 | 7.714758 | 0.001566 | 0.028757 |
| hsa-miR-5094 | 5.125813 | 1.680093 | 0.002864 | 0.04123 |
FC fold change, CPM read per million, FDR false discovery rate
Functional pathways identified in mRNA targets for miRNAs
| p value | Number of miRNAs in each pathway | |
|---|---|---|
| Pathways in bacterial digestion | ||
| Proteasome | 0.0139 | 3 |
| Ubiquitin-mediated proteolysis | 0.0057 | 7 |
| Pathways in infection process | ||
| Bacterial invasion of epithelial cells | 0.0310 | 7 |
| Endocytosis | 0.0337 | 8 |
| ECM-receptor interaction | 0.00153 | 4 |
| Adherents junction | 0.00730 | 4 |
| Inositol phosphate metabolism | 0.00201 | 4 |
| Pathways in fatty acid metabolism | ||
| Fatty acid biosynthesis | 0.00000000684 | 3 |
| Fatty acid metabolism | 0.00000154 | 5 |
| Fatty acid elongation | 0.000738 | 3 |
| Steroid biosynthesis | 0.00631 | 3 |
| 2-Oxocarboxylic acid metabolism | 0.0165 | 3 |
| Pathways in amino acids metabolism | ||
| Phenylalanine, tyrosine and tryptophan biosynthesis | 0.000713 | 3 |
| Valine, leucine and isoleucine degradation | 0.0310 | 6 |
| Lysine degradation | 0.0421 | 6 |
| Pathways for energy production and sugar metabolism | ||
| Central carbon metabolism | 0.00435 | 5 |
| 2-Oxocarboxylic acid metabolism | 0.0165 | 3 |
| Glycosaminoglycan biosynthesis—heparan sulfate/heparin | 0.0113 | 3 |
| Proteoglycans | 0.0337 | 8 |
| Cell signaling pathways | ||
| Phosphatidylinositol signaling system | 0.0489 | 5 |
| TGF-beta signaling pathway | 0.0489 | 4 |
The number of genes targeted by the miRNAs in the altered pathways
| Pathways | Gene | p value |
|---|---|---|
| Pathways in fatty acid metabolism | ||
| Fatty acid biosynthesis | 2 | 0.000000000684 |
| Fatty acid metabolism | 12 | 0.00000154 |
| Fatty acid elongation | 7 | 0.000738 |
| Steroid biosynthesis | 6 | 0.00631 |
| 2-Oxocarboxylic acid metabolism | 6 | 0.0165 |
| Pathways in amino acids metabolism | ||
| Phenylalanine, tyrosine and tryptophan biosynthesis | 4 | 0.000713 |
| Valine, leucine and isoleucine degradation | 12 | 0.0310 |
| Lysine degradation | 16 | 0.0421 |
| Pathways of energy production and sugar metabolism | ||
| Central carbon metabolism in cancer | 19 | 0.00435 |
| 2-Oxocarboxylic acid metabolism | 6 | 0.0165 |
| Glycosaminoglycan biosynthesis—heparan sulfate/heparin | 9 | 0.0113 |
| Proteoglycans | 49 | 0.0337 |
| Pathways in infection | ||
| Bacterial invasion of epithelial cells | 23 | 0.0310 |
| Endocytosis | 51 | 0.0337 |
| ECM-receptor interaction | 16 | 0.00153 |
| Adheres junction | 21 | 0.00730 |
| Inositol phosphate metabolism | 15 | 0.0201 |
| Cell signaling pathways | ||
| Phosphatidylinositol signaling system | 21 | 0.0489 |
| TGF-beta signaling pathway | 18 | 0.0489 |
| Pathways in bacterial digestion | ||
| Proteasome | 3 | 0.0138 |
| Ubiquitin mediated proteolysis | 7 | 0.00566 |
The number of target genes regulated by the differentially expressed miRNAs in the dysregulated pathways
| Pathways | Differentially expressed miRNA | Number target genes |
|---|---|---|
| Bacterial invasion pathway | hsa-miR-484 | 15 |
| hsa-miR-6848- | 4 | |
| hsa-miR-5094 | 1 | |
| hsa-miR-425-5p | 9 | |
| hsa-miR-1293 | 2 | |
| hsa-miR-4488-5p | ||
| hsa-miR-1224-5p | 1 | |
| hsa-miR-4732- | 1 | |
| Fatty acid biosynthesis pathways | hsa-miR-1293 | 1 |
| hsa-miR-484 | 1 | |
| hsa-miR-425-5p | 1 | |
| Fatty acid metabolism | hsa-miR-5094 | 2 |
| hsa-miR-425-5p | 4 | |
| hsa-miR-1293 | 3 | |
| hsa-miR-484 | 4 | |
| hsa-miR-6849- | 1 | |
| Trp/phe synthesis | hsa-miR-6848- | 1 |
| hsa-miR-4467 | 1 | |
| hsa-miR-484 | 2 | |
| Fatty acid elongation | hsa-miR-425-5p | 4 |
| hsa-miR-484 | 2 | |
| hsa-miR-5094 | 1 | |
| Central carbon metabolism | hsa-miR-1224-5p | 5 |
| hsa-miR-484 | 10 | |
| Has-mir-96 | ||
| hsa-miR-425-5p | 6 | |
| hsa-miR-6848- | 1 | |
| hsa-miR-6849- | 1 | |
| Steroid biosynthesis | hsa-miR-484 | 4 |
| hsa-miR-4732- | 1 | |
| hsa-miR-425-5p | 3 | |
| Glucose amino glycan | hsa-miR-484 | 4 |
| hsa-miR-6848- | 2 | |
| hsa-miR-5094 | 1 | |
| hsa-miR-1293 | 1 | |
| hsa-miR-1224-5p | 1 | |
| hsa-miR-6849- | 1 | |
| 2′-Oxycarboxyl | hsa-miR-484 | 4 |
| Has-miR-96 | ||
| hsa-miR-6848- | 2 | |
| hsa-miR-5094 | 1 | |
| hsa-miR-1293 | 1 | |
| hsa-miR-1224-5p | 1 | |
| hsa-miR-6849- | 1 | |
| Val/leu/isoleu synthesis | hsa-miR-484 | 5 |
| hsa-miR-4732- | 2 | |
| hsa-miR-5094 | 3 | |
| hsa-miR-425-5p | 1 | |
| hsa-miR-4467 | 1 | |
| hsa-miR-1293 | 1 | |
| Proteoglycan | hsa-miR-5094 | 5 |
| hsa-miR-484 | 27 | |
| hsa-miR-425-5p | 17 | |
| hsa-miR-1293 | 2 | |
| hsa-miR-1224-5p | 4 | |
| hsa-miR-4732- | 2 | |
| hsa-miR-6849- | 3 | |
| hsa-miR-6848- | 4 | |
| Lysine degradation | hsa-miR-484 | 11 |
| hsa-miR-5094 | 3 | |
| hsa-miR-1293 | 4 | |
| hsa-miR-425-5p | 4 | |
| hsa-miR-6848- | 1 | |
| hsa-miR-1224-5p | 1 |